Context Therapeutics Inc. (CNTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US21077P1084
Context Therapeutics Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -39.70 m USD |
| EBIT | -39.50 m USD |
| Net income | -36.12 m USD |
| Diluted EPS – continuing operations | -0.38 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Context Therapeutics Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
More stocks
- TRANSUITE.ORG INC. (TRSO)
- Western Uranium & Vanadium Corp. (WSTRF)
- Jaguar Uranium Corp. (JAGU)
- Longduoduo Co Ltd (LDDD)
- Investcorp Credit Management BDC, Inc. (ICMB)
- BuzzFeed, Inc. (BZFD)
- INTELLIGENT PROTECTION MANAGEMENT CORP. (IPM)
- Presurance Holdings, Inc. (PRHI)
- Cue Biopharma, Inc. (CUE)
- Beeline Holdings, Inc. (BLNE)
- Security Midwest Bancorp, Inc. (SBMW)
- Starco Brands, Inc. (STCB)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.